ITOS Stock Overview
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$39.66|
|52 Week High||US$52.43|
|52 Week Low||US$17.43|
|1 Month Change||-8.19%|
|3 Month Change||43.54%|
|1 Year Change||12.90%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||108.19%|
Recent News & Updates
Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic
Celebrations may be in order for iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) shareholders, with the analysts delivering a...
|ITOS||US Biotechs||US Market|
Return vs Industry: ITOS exceeded the US Biotechs industry which returned -14.3% over the past year.
Return vs Market: ITOS matched the US Market which returned 13.7% over the past year.
|ITOS Average Weekly Movement||8.0%|
|Biotechs Industry Average Movement||10.0%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.9%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: ITOS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ITOS's weekly volatility (8%) has been stable over the past year.
About the Company
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company’s product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
iTeos Therapeutics Fundamentals Summary
|ITOS fundamental statistics|
Is ITOS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ITOS income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.42|
|Net Profit Margin||14.14%|
How did ITOS perform over the long term?See historical performance and comparison
Is iTeos Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ITOS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ITOS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ITOS is poor value based on its PE Ratio (94.9x) compared to the US Biotechs industry average (24.4x).
PE vs Market: ITOS is poor value based on its PE Ratio (94.9x) compared to the US market (17.4x).
Price to Earnings Growth Ratio
PEG Ratio: ITOS's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: ITOS is overvalued based on its PB Ratio (3.8x) compared to the US Biotechs industry average (2.2x).
How is iTeos Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ITOS's earnings are forecast to decline over the next 3 years (-54.5% per year).
Earnings vs Market: ITOS's earnings are forecast to decline over the next 3 years (-54.5% per year).
High Growth Earnings: ITOS's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ITOS's revenue is expected to decline over the next 3 years (-16.9% per year).
High Growth Revenue: ITOS's revenue is forecast to decline over the next 3 years (-16.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ITOS's Return on Equity is forecast to be low in 3 years time (0.5%).
How has iTeos Therapeutics performed over the past 5 years?
Historical Pharmaceuticals & Biotech annual earnings growth
Earnings and Revenue History
Quality Earnings: ITOS has high quality earnings.
Growing Profit Margin: ITOS became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: ITOS has become profitable over the past 5 years.
Accelerating Growth: ITOS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ITOS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: ITOS's Return on Equity (4%) is considered low.
How is iTeos Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ITOS's short term assets ($914.1M) exceed its short term liabilities ($542.2M).
Long Term Liabilities: ITOS's short term assets ($914.1M) exceed its long term liabilities ($8.1M).
Debt to Equity History and Analysis
Debt Level: ITOS is debt free.
Reducing Debt: ITOS has not had any debt for past 5 years.
Debt Coverage: ITOS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ITOS has no debt, therefore coverage of interest payments is not a concern.
What is iTeos Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ITOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ITOS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ITOS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ITOS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ITOS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Michel Detheux (55 yo)
Dr. Michel Detheux, Ph D, serves as an Independent Chairman at Ona Therapeutics, S.L. since December 2021. He has served as the Chief Executive Officer and Director at iTeos Therapeutics, Inc. since August...
CEO Compensation Analysis
Compensation vs Market: Michel's total compensation ($USD16.82M) is above average for companies of similar size in the US market ($USD3.62M).
Compensation vs Earnings: Michel's compensation has been consistent with company performance over the past year.
Experienced Management: ITOS's management team is considered experienced (2.4 years average tenure).
Experienced Board: ITOS's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ITOS insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
iTeos Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: iTeos Therapeutics, Inc.
- Ticker: ITOS
- Exchange: NasdaqGM
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.399b
- Shares outstanding: 35.27m
- Website: https://www.iteostherapeutics.com
Number of Employees
- iTeos Therapeutics, Inc.
- 139 Main Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/16 23:14|
|End of Day Share Price||2022/01/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.